Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions

Leukemia Research

Volumn 38, Issue 7, 2014, Pages 764-772

  Gotta, Verena ^a,b   Bouchet, Stephane ^c   Widmer, Nicolas ^a   Schuld, Peter ^d   Decosterd, Laurent A ^a   Buclin, Thierry ^a   Mahon, Francois Xavier ^e   Csajka, Chantal ^a,b   Molimard, Mathieu ^d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Haematology and Professional Relations   (Italy)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chronic myelogenous leukemia; Dose response relationship; Drug monitoring; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4 INIHIBITOR; GLYCOPROTEIN P INHIBITOR; HUMAN ORGANIC CATION TRANSPORTER 1 INHIBITOR; IMATINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERANCE; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; FLUID RETENTION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SKIN DISEASE; TREATMENT RESPONSE;

CHRONIC MYELOGENOUS LEUKEMIA; DOSE-RESPONSE RELATIONSHIP; DRUG MONITORING; PHARMACODYNAMICS; PHARMACOKINETICS; THERAPEUTIC DRUG MONITORING; TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84902110431     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.023     Document Type: Article

References (41)

1. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
2. Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annu Meet Abstr 2009, 114:1126.
3. Shami P.J., Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012, 26:214-224.
4. Roychowdhury S., Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Rev 2011, 25:279-290.
5. Cortes J.E., Egorin M.J., Guilhot F., Molimard M., Mahon F.X. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23:1537-1544.
6. Bulletin Board EUTOS for chronic myeloid leukemia shows improved management and dose optimization is required. Future Oncol 2008, 4:758.
7. European Treatment and Outcome Study (EUTOS) Path to cure: about the subproject pharmacological monitoring 2011, http://www.eutos.org/content/path_to_cure [accessed 01.09.12].
8. Teng J.F.T., Mabasa V.H., Ensom M.H.H. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 2012, 34:85-97.
9. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
10. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
11. Roth O., Spreux-Varoquaux O., Bouchet S., Rousselot P., Castaigne S., Rigaudeau S., et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin Chim Acta 2010, 411:140-146.
12. Bouchet S., Chauzit E., Ducint D., Castaing N., Canal-Raffin M., Moore N., et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011, 412:1060-1067.
13. Zhou S.-F., Xue C.C., Yu X.-Q., Li C., Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007, 29:687-710.
14. Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011, 117:e75-e87.
15. Centre d'informations thérapeutique et de pharmacovigilance - HÔpitaux Universitaires de Genève Table des interaction médicamenteuses et cytochromes P450 2009, http://www.pharmacoclin.ch/_library/pdf/cytp450 [accessed 01.03.10].
16. Ahlin G., Karlsson J., Pedersen J.M., Gustavsson L., Larsson R., Matsson P., et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 2008, 51:5932-5942.
17. White D.L., Saunders V.A., Dang P., Engler J., Zannettino A.C.W., Cambareri A.C., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108:697-704.
18. FDA U.S.Food and Drug Administration Drug development and drug interactions table of substrates, inhibitors and inducers 2011, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm [accessed 14.12.10].
19. Judson I., Ma P., Peng B., Verweij J., Racine A., di Paola E.D., et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC soft tissue and bone sarcoma group. Cancer Chemother Pharmacol 2005, 55:379-386.
20. Yoo C., Ryu M.-H., Ryoo B-Y., Beck M.Y., Chang H-M., Lee J-L., et al. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest New Drugs 2012, 30:1703-1708.
21. Menon-Andersen D., Mondick J.T., Jayaraman B., Thompson P.A., Blaney S.M., Bernstein M., et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 2009, 63:229-238.
22. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
23. Li-Wan-Po A., Farndon P., Craddock C., Griffiths M. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol 2010, 66:369-374.
24. Ishikawa Y., Kiyoi H., Watanabe K., Miyamura K., Nakano Y., Kitamura K., et al. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 2010, 101:2186-2192.
25. Pemmaraju N., Kantarjian H., Shan J., Jabbour E., Quintas-Cardama A., Verstovsek S., et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 2012, 97:1029-1035.
26. Bouchet S., Titier K., Moore N., Lassalle R., Ambrosino B., Poulette S., et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol 2013, 27:690-697.
27. Branford S., Yeung D.T., Ross D.M., Prime J.A., Field C.R., Altamura H.K., et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013, 121:3818-3824.
28. Noens L., van Lierde M.-A., De Bock R., Verhoef G., Zachée P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
29. Marin D., Bazeos A., Mahon F.-X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
30. Gotta V., Buclin T., Csajka C., Widmer N. Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Ther Drug Monit 2013, 35:150-167.
31. Eechoute K., Fransson M.N., Reyners A.K., de Jong F.A., Sparreboom A., van der Graaf W.T.A., et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012, 18:5780-5787.
32. Chatelut E., Gandia P., Gotta V., Widmer N. Long-term prospective population PK study in GIST patients-letter. Clin Cancer Res 2013, 19:949.
33. Schmidli H., Peng B., Riviere G-J., Capdeville R., Hensley M., Gathmann I., et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005, 60:35-44.
34. Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006, 62:97-112.
35. Delbaldo C., Chatelut E., Ré M., Deroussent A., Séronie-Vivien S., Jambu A., et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12:6073-6078.
36. Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., et al. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol 2013, 75:1007-1018.
37. Gibbons J., Egorin M.J., Ramanathan R.K., Fu P., Mulkerin D.L., Shibata S., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008, 26:570-576.
38. Fahrmayr C., Fromm M.F., König J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 2010, 42:380-401.
39. Breccia M., Cannella L., Stefanizzi C., Latagliata R., Nanni M., Diverio D., et al. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematol Oncol 2010, 28:89-92.
40. Baccarani M., Rosti G., Castagnetti F., Haznedaroglu I., Porkka K., Abruzzese E., et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
41. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.